Michael Babich, the Arizona-based drugmaker’s former chief executive officer, and others were charged with participating in a conspiracy in which bribes were disguised as marketing event and speaker fees. The case is the latest involving Subsys, a spray approved for managing pain in cancer patients that contains the synthetic opioid fentanyl, as authorities try to stem a nationwide epidemic of opioid abuse. Shares of Insys were down 11.87 percent, or $1.27, to close at $9.43 on the NASDAQ on Thursday.
Go here to read the rest:
Ex-Insys executives arrested for bribing U.S. doctors to prescribe painkiller
